Breakthrough in Ophthalmology! Hengrui's Heng Qin® (Perfluorohexyloctane Eye Drops) Approved as First Treatment for Dry Eye Disease Associated with MGD
According to the Chinese Expert Consensus on MGD: Diagnosis and Treatment in 2023, there is no drug that directly targets the treatment of MGD 1. The incidence rate of DED in China is 21%-30% according to the Clinical Guidelines for Diagnosis and Treatment of Dry Eye 2. Epidemiology studies show that 69%-86% of DED patients suffer from evaporative DED, the most common disease subtype resulting from MGD 3,4. Hengrui aims to address the urgent and common clinical need for an effective and safe treatment for the treatment of DED associated with MGD.
Heng Qin ® (Perfluorohexyloctane Eye Drops) is based on EyeSol ®, the world's first water-, excipient-, and preservative-free drug technology 5,6. Due to its low surface tension 5, it rapidly spreads over the ocular surface 7. It improves the tear lipid layer, inhibits tear evaporation, and promotes corneal epithelial healing 8,9. In addition, perfluorohexyloctane supplements nonpolar lipids in the lipid layer, increases tear film thickness and improves Meibomian gland function 8,9.
The NMPA approval of Heng Qin ® was based on a multi-center, randomized, controlled, double-blind, pivotal phase 3 clinical study in Chinese patients 8. The study demonstrated that Heng Qin ® compared with an active comparator, 0.6% saline solution, significantly improved the clinical signs and symptoms of patients with DED associated with MGD as early as 2 weeks and at day 29, respectively. The effects were maintained through day 57, the end of the study. According to the study findings, Heng Qin ® is safe and well-tolerated. The incidence of instillation site reactions following administration of the eye drops is low and comparable to the study comparator.
In 2019, Hengrui Pharma and Novaliq announced a strategic collaboration under which Hengrui Pharma secured exclusive rights to develop, manufacture, and commercialize perfluorohexyloctane (development name: SHR8058 eye drops) in China. Perfluorohexyloctane ophthalmic solution was approved as dry eye drug therapy in the United States and in Canada in May 2023 and September 2024, respectively.
About Hengrui Pharma
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) is an innovative, global pharmaceutical company dedicated to the research, development and commercialization of high-quality medicines to address unmet clinical needs. With a global R&D team that includes 14 R&D centers and more than 5,500 professionals, Hengrui Pharma's therapeutic areas of focus include oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. To date, Hengrui has commercialized 23 new molecular entity drugs and 4 other innovative drugs in China. Founded in 1970 with the core principle of putting patients first, Hengrui Pharma remains committed to advancing human health by striving to conquer diseases, improve health, and extend lives through the power of science and technology.
About Novaliq
Novaliq is a private biopharmaceutical company focusing on the development of first- and best-in-class ocular therapeutics. Novaliq developed EyeSol ®, a novel drug category of water-free topical eye medicines. Two FDA-approved EyeSol ® medicinal products for dry eye disease – Miebo ® and Vevye ® – are on the market in the United States revolutionizing patient care. The Novaliq R&D pipeline provides multiple development opportunities in ophthalmology and retina therapies. Novaliq is headquartered in Heidelberg, Germany and has an office in Cambridge, MA, USA. The long-term single shareholder is dievini Hopp BioTech holding GmbH & Co. KG, an active investor in Life and Health Sciences companies. More on www.novaliq.com.
Reference
Chinese Branch of the Asian Dry Eye Society, Ocular Surface and Tear Film Diseases Group of Ophthalmology Committee of Cross‑Straits Medicine Exchange Association, & Ocular Surface and Dry Eye Group of Chinese Ophthalmologist Association (2023). [Zhonghua yan ke za zhi] Chinese journal of ophthalmology. 2023 Nov 11; 59(11), 880–887. doi: 10.3760/cma.j.cn112142-20230822-00054.
Clinical Guidelines for Diagnosis and Treatment of Dry Eye. ISBN: 9787523506189
Jie Y, Xu L, Wu YY, Jonas JB. Prevalence of dry eye among adult Chinese in the Beijing Eye Study. Eye (Lond). 2009 Mar;23(3):688–693. doi: 10.1038/sj.eye.6703101.
Lemp MA, Crews LA, Bron AJ, Foulks GN, Sullivan BD. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea. 2012 May;31(5):472-8. doi: 10.1097/ICO.0b013e318225415a.
Tsagogiorgas C, Otto M. Semifluorinated Alkanes as New Drug Carriers-An Overview of Potential Medical and Clinical Applications. Pharmaceutics. 2023 Apr 11;15(4):1211. doi: 10.3390/pharmaceutics15041211.
Sheppard JD, et al. MOJAVE Study Group. NOV03 for Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction: The Randomized Phase 3 MOJAVE Study. Am J Ophthalmol. 2023 Aug;252:265-274. doi: 10.1016/j.ajo.2023.03.008.
Agarwal P, et al. Preclinical studies evaluating the effect of semifluorinated alkanes on ocular surface and tear fluid dynamics. Ocul Surf. 2019 Apr;17(2):241-249. doi: 10.1016/j.jtos.2019.02.010.
Vittitow J, et al. In Vitro Inhibition of Evaporation with Perfluorohexyloctane, an Eye Drop for Dry Eye Disease. Curr Ther Res Clin Exp. 2023 May 12;98:100704. doi: 10.1016/j.curtheres.2023.100704.
Steven P, et al. Semifluorinated Alkane Eye Drops for Treatment of Dry Eye Disease Due to Meibomian Gland Disease. J Ocul Pharmacol Ther. 2017 Nov;33(9):678-685. doi: 10.1089/jop.2017.0042.
Tian L, et al. Perfluorohexyloctane Eye Drops for Dry Eye Disease Associated With Meibomian Gland Dysfunction in Chinese Patients: A Randomized Clinical Trial. JAMA Ophthalmol. 2023 Apr 1;141(4):385-392. doi: 10.1001/jamaophthalmol.2023.0270.
Any product/brand names and/or logos are trademarks of their respective owners. © 2025 Jiangsu Hengrui Pharmaceuticals Co., Ltd. and Novaliq GmbH, Heidelberg, Germany. All rights reserved.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
7 hours ago
- Business Wire
Shore Surgery Specialist Day Hospital Selects Provation ® to Streamline Endoscopy Documentation and Advance Quality Improvement
AUCKLAND, New Zealand--(BUSINESS WIRE)--Provation, the trusted healthcare software partner for advanced procedure documentation, today announced that Shore Surgery Specialist Day Hospital, part of Evolution Healthcare, has successfully gone live with Provation ® for endoscopy documentation. Shore Surgery is the fourth Evolution Healthcare site to adopt Provation, underscoring the group's commitment to data-driven care and operational excellence across its network. 'Provation standardises reports, integrates procedure images, and enables advanced audit capabilities—all while saving valuable minutes per case. Early feedback shows high user satisfaction and adoption.' Shore Surgery's two-theatre, same-day facility performs gastroenterology, endoscopy, gynaecology, ophthalmology, and plastic-reconstructive procedures for patients throughout Auckland. The day surgery conducts benchmarking through multiple national and international quality programs, which is a key component of the group's quality systems and enables Shore Surgery to identify opportunities to improve health outcomes and promote a culture of excellence. 'Our clinicians described the previous reporting workflow as clunky, slow, and audit-limited,' said the Endoscopy Team Leader at Shore Surgery. 'Provation standardises reports, integrates procedure images, and enables advanced audit capabilities—all while saving valuable minutes per case. Early feedback shows high user satisfaction and adoption.' Before Provation, Shore Surgery relied on manually built templates with drop-down fields and separate photo printing, or dictation that required later transcription. By moving to Provation, Shore Surgery now benefits from: Faster, structured documentation with integrated images and intelligent drop-down selections Immediate, consistent report delivery to consulting rooms and patient management systems Robust capability to clinically audit that supports Evolution Healthcare's benchmarking program and quality management framework 'Evolution Healthcare, and Shore Surgery in particular, has long prioritised objective performance measurement,' noted the Administration Manager at Shore Surgery Specialist Day Hospital. 'Adding Provation at Shore Surgery strengthens our data foundation and empowers clinicians to focus more time on patient care.' 'We are thrilled to expand our partnership with Evolution Healthcare,' added Ankush Kaul, President of Provation. 'Shore Surgery's rapid go-live and strong user satisfaction exemplify how purpose-built documentation software accelerates quality improvement for private day hospitals across New Zealand.' About Shore Surgery Specialist Day Hospital Shore Surgery Specialist Day Hospital is a multi-specialty facility in Auckland's North Shore, New Zealand, offering gastroenterology, endoscopy, gynaecology, ophthalmology, and plastic-reconstructive services. With two operating theatres and a dedicated five-bed recovery suite, the hospital enables patients to be discharged safely on the same day. Shore Surgery is part of Evolution Healthcare, which operates hospitals, day surgeries, a maternity hospital and specialist health and wellbeing across New Zealand. For more information visit About Provation Provation is a leading healthcare software provider dedicated to empowering providers with innovative solutions that streamline clinical workflows in the Gastroenterology and Anaesthesia specialties. Provation's platforms are trusted by over 5,000 hospitals, surgery centers, and medical offices globally. With a purpose-driven approach, Provation continues to drive productivity and improve patient outcomes through advanced documentation and workflow solutions. For more information, visit and follow us on Twitter, Facebook, and LinkedIn.
Yahoo
11 hours ago
- Yahoo
The Final Countdown for New CMS Glycemic Measures: Glytec Prepares Hospitals and Health Systems with Proven, FDA-Cleared Technology Platform
167 Days to Prepare for the New Federal Reporting Requirements for Hypo- and Hyperglycemia BOSTON, July 17, 2025 /PRNewswire/ -- Glytec is the leading provider of an AI-powered technology platform for diabetes and related conditions, including its FDA-cleared Glucommander® EHR-integrated solution for inpatient glycemic management. Today, Glytec reinforced its commitment to supporting U.S. hospitals in preparation for the upcoming Centers for Medicare & Medicaid Services (CMS) mandate on inpatient glycemic control reporting. With the measurement period set to begin on January 1, 2026, and just 167 days remaining, now is an important time for hospitals to begin preparing. Equipping teams with the right tools, workflows, and data systems can help ensure readiness for these critical requirements—and avoid potential reductions in Medicare reimbursement starting in fiscal year 2028. Under the new mandate, CMS will require reporting of both severe hypoglycemia (blood glucose <40 mg/dL) and severe hyperglycemia (blood glucose >300 mg/dL) as electronic clinical quality measures (eCQMs). These measures apply to nearly 40% of hospitalized patients who experience dysglycemia during their stay. "CMS is creating focus and awareness around inpatient diabetes care," said Patrick Cua, CEO of Glytec. "This will help drive improved patient care and patient safety, but hospitals also have revenue to gain via reduced length of stay and cost avoidance through reduced hypoglycemia, lower testing costs, and improved workflows. Glytec's platform is purpose-built to lead hospitals through this transition safely and to continue to innovate around diabetes workflows to drive better patient care and overall economics for healthcare stakeholders." The new CMS reporting mandate is driven in part by the increasing prevalence of diabetes and its associated complications, which place a significant burden on healthcare systems, payors, and individual lives. More than one-third of hospitalized patients require insulin therapy to manage elevated blood glucose levels during their stay [1]. Each year, more than 2 million patients experience adverse events in the hospital related to hypoglycemia—events that, according to the Agency for Healthcare Research and Quality (AHRQ), contribute to over $8 billion in costs and are associated with increased length of stay and higher readmission rates. Despite the widespread impact of glycemic events, nearly one-third of hospitals do not track glucose management metrics, and 59% lack automated methods to collect data on rates of hyperglycemia and hypoglycemia [2]. In response, some institutions have developed internal solutions, which, while well-intentioned, may introduce challenges related to clinical oversight, regulatory alignment, and the safe management of a high-risk therapy like insulin. Technology Built for Clinical Excellence and Return on Investment The Glytec Technology Platform, leveraged by over 400 hospitals, manages complex, high-impact workflows—from hospital to home—with proven results and AI-driven intelligence. It is built on over 100 patents, 100 clinical publications, 16 years of experience, and 50+ billion data points. As an FDA-cleared platform, Glytec provides: Industry superior insulin dosing algorithms with ongoing clinical validation, monitoring, and venture-backed investment Real-time dashboards aligned with CMS reporting requirements Turn-key EHR integration, enhanced cybersecurity, and reducing IT burden and overhead Freedom to operate across the breadth of Glytec's 100+ patented algorithms, workflows, and other intellectual property. In-House Insulin Tools Fall Short Some hospitals have explored building their own in-house insulin calculators to manage glycemia, but studies and real-world feedback reveal that these solutions: Lack clinical validation, scalability, and rigor of FDA-cleared solutions Can introduce user interface challenges and omit clinical guardrails that contribute to dosing errors and patient harm Require ongoing maintenance and investment that cannot keep pace with dedicated venture-backed technology companies, and Divert critical IT staff from broader strategic hospital technology objectives 167 Days and Counting to Get It Right The countdown is on. As the CMS mandate nears, hospitals must choose partners to deliver speed, safety, and scale, and avoid the cost, delay, and proven lower outcomes of risky non-regulated approaches. About Glytec Glytec's industry-leading technology platform, trusted by over 400 hospitals, empowers collaborative diabetes management and insulin dosing, improving patient outcomes, reducing hospital length of stay, and optimizing clinical workflows. Its flagship product, Glucommander®—the first-ever FDA-cleared cloud-based insulin management software—integrates seamlessly with EMRs, providing advanced clinical decision support, workflow alerts, patient monitoring, and AI-driven analytics. Supported by over 100 patents and 100 peer-reviewed publications, Glytec is dedicated to improving care from hospital to home. For more information, visit or follow Glytec on LinkedIn. Media Contact: Public RelationsGlytecPR@ References: Umpierrez GE, et al. Journal of Clinical Endocrinology & Metabolism, 87(3), 978–982. (March 2002). Cook CB, et al. Endocrine Practice, 16(2), 219–230. (March 2010). View original content to download multimedia: SOURCE Glytec, LLC
Business Upturn
16 hours ago
- Business Upturn
Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline
– Proven In-Office, Repeatable, Non-Surgical Procedure for the Targeted Delivery of a Wide Variety of Therapies for Serious Retinal Diseases – – CLS-AX Phase 3-Ready Asset with Global Investigator Support and FDA Alignment on Pivotal Trial Program in wet AMD – – Validated Delivery Platform with Five Commercial and Late-Stage Development Suprachoroidal Licensing Collaborations – ALPHARETTA, Ga., July 17, 2025 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today announced plans to explore a full range of strategic alternatives to advance its SCS platform and drug development pipeline to maximize stockholder value. The Company has retained Piper Sandler, a leading investment bank with substantial experience in the biotechnology industry, to support it with the strategic evaluation process. Strategic alternatives under consideration include the sale, license, monetization and/or divestiture of one or more of the Company's assets and technologies, collaboration, partnership, merger, acquisition, joint ventures, or other strategic transactions. 'We strongly believe that our proprietary suprachoroidal delivery platform provides an effective and reliable way to target challenging retinal diseases that need longer lasting treatments,' said George Lasezkay, PharmD, JD, President and Chief Executive Officer. 'Our SCS Microinjector® enables a proven in-office, repeatable, non-surgical procedure for the targeted delivery of a wide variety of therapies to the macula, retina, and choroid. Based on our retinal expertise and intellectual property, we delivered the first commercial product using our SCS platform, which is now approved and commercialized in the U.S., approved in Singapore and Australia, and is currently under regulatory review in China and Canada.' Dr. Lasezkay further stated, 'We have successfully produced positive and highly competitive Phase 2b clinical data for CLS-AX for the treatment of wet AMD. We are proud of the fact that the CLS-AX ODYSSEY Phase 2b trial is the only TKI clinical trial to date to achieve positive safety and efficacy results from multiple TKI dosing in wet AMD patients. Further, in February 2025, we conducted a successful end of Phase 2 meeting with the FDA through which we gained alignment on a Phase 3 development plan for CLS-AX in wet AMD. In addition, our clinical development collaboration partners continue to make progress in advancing their later-stage suprachoroidal clinical programs utilizing our SCS Microinjector in various ophthalmic disorders.' Dr. Lasezkay continued, 'Clearside's innovative and pioneering achievements demonstrating the safety, simplicity and effectiveness of delivering drugs to the suprachoroidal space are the direct result of the many years of significant contributions by the current Clearside team and many of our past employees. I am proud of and grateful for their hard work and dedicated commitment to improving the lives of patients suffering from the burden of disabling, blinding diseases.' 'Given the current unpredictable economic environment and challenging fundraising conditions in the biopharmaceutical industry, we are taking the necessary next steps to evaluate strategic alternatives for the Company. In order to facilitate this process and conserve cash, while continuing our support of the Company's SCS Microinjector® licensees, all Clearside employees, including the Chief Executive Officer, Chief Financial Officer, and Chief Medical Officer, will transition into consulting roles with the Company this week. In addition, we will pause all internal research and development programs during this process,' concluded Dr. Lasezkay. No agreement providing for any strategic transaction has been reached and there can be no assurance that this process will result in any such transaction. Clearside has not set a timetable for the strategic review process. Clearside does not intend to provide updates until the Board approves a specific action or otherwise determines that disclosure is appropriate or required. Company Highlights SCS Injection Platform: The SCS Microinjector is a proven in-office, repeatable, non-surgical procedure for the targeted delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside has formulation expertise in developing small molecule suspensions that can be delivered into the suprachoroidal space, and commercial scale manufacturing capability for the SCS Microinjector that includes ISO certification. The Company successfully navigated the U.S. Food & Drug Administration (FDA) drug/device regulatory pathway to obtain commercial approval for its first product, XIPERE ® (triamcinolone acetonide injectable suspension) for suprachoroidal use for the treatment of uveitic macular edema. (triamcinolone acetonide injectable suspension) for suprachoroidal use for the treatment of uveitic macular edema. A permanent CPT code is assigned in the U.S. for suprachoroidal injections permitting physicians to receive higher reimbursement for administering any drug into the SCS versus the reimbursement of the current practice of injecting drugs into the vitreous. Internal Pipeline – CLS-AX Program: CLS-AX (axitinib injectable suspension) is a proprietary suspension of axitinib for suprachoroidal injection. CLS-AX is being developed for the treatment of neovascular age-related macular degeneration (wet AMD). Axitinib is a tyrosine kinase inhibitor (TKI) that achieves pan-VEGF blockade, directly inhibiting VEGF receptors-1, -2, and -3 with high potency and specificity. Clearside believes this broad VEGF blockade may have efficacy advantages over existing retinal therapies by acting at a different level of the angiogenesis cascade and may benefit patients who sub-optimally respond to current, more narrowly focused anti-VEGF therapies. Age-related macular degeneration causes a progressive loss of central vision and is the most common cause of legal blindness in individuals over age 55. Wet AMD is generally caused by abnormal blood vessels that leak fluid or blood into the macula, the part of the retina responsible for central vision, and accounts for the majority of vision loss in patients with this disorder. Suprachoroidal injection of CLS-AX has demonstrated meaningful potential in Phase 1/2a and Phase 2b wet AMD clinical trials. These data strongly support the potential efficacy, safety and versatility of CLS-AX to treat this chronic disease. Clearside conducted a successful End-of-Phase 2 meeting with the FDA and aligned on the essential components of a Phase 3 program. The Phase 3 program is designed to maximize the commercial potential for CLS-AX with the potential to provide physicians and their patients with dosing flexibility similar to the current standard of care anti-VEGF biologics, but with the extended durability of a TKI. This combination of dosing flexibility and durability may improve outcomes and reduce the treatment burden for patients suffering from these potentially blinding retinal disorders, as well as their caregivers. Internal Pipeline – Preclinical Small Molecule Programs: Clearside is evaluating various small molecules for a range of retinal diseases with high unmet medical need. Clearside is evaluating preclinical data on two approaches targeting Geographic Atrophy (GA) – improving choroidal perfusion and modulating pro-inflammatory cells. GA is a progressive, late-stage form of dry age-related macular degeneration characterized by well-defined areas of retinal cell loss in the macula, leading to irreversible central vision impairment. Delivery of small molecules via suprachoroidal injection enables comprehensive drug coverage of both the retina and choroid, while also potentially minimizing systemic and anterior segment side effects. Clearside is evaluating preclinical data on the combination of a steroid plus a TKI (axitinib formulation) for the treatment of Diabetic Macula Edema (DME). DME is the most common cause of vision loss in individuals with diabetes, in which fluid accumulates in the central part of the retina causing swelling and vision distortion due to leaky blood vessels damaged by prolonged high blood sugar. External Licensing Agreements: Clearside strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic agents including gene therapies and anti-tumor agents. Clearside's innovative SCS Microinjector is being used in commercial ophthalmic products and promising clinical development programs by Aura Biosciences, Bausch + Lomb, BioCryst Pharmaceuticals, REGENXBIO and its global partner AbbVie, and Arctic Vision and its commercial partner Santen. About Clearside Biomedical, Inc. Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®) to improve patient outcomes. Clearside's SCS injection platform, utilizing the Company's patented SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company's lead program, CLS-AX (axitinib injectable suspension), is in development for the treatment of neovascular age-related macular degeneration (wet AMD). Planning for a Phase 3 program is underway. In addition, Clearside is evaluating various small molecules for the potential long-acting treatment of geographic atrophy (GA). Clearside developed and gained approval for its first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the U.S. through a commercial partner. Clearside also strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. For more information, please visit or follow us on LinkedIn and X. Cautionary Note Regarding Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as 'believe', 'expect', 'may', 'plan', 'potential', 'will', and similar expressions, and are based on Clearside's current beliefs and expectations. These forward-looking statements include statements regarding the clinical development of CLS-AX, including the planned Phase 3 trial design, the potential benefits of CLS-AX, Clearside's suprachoroidal delivery technology and Clearside's SCS Microinjector®, and Clearside's pursuit of strategic alternatives and the entry into or completion of any strategic alternative transaction. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Clearside's reliance on third parties over which it may not always have full control, Clearside's ability to raise additional capital, and other risks and uncertainties that are described in Clearside's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (SEC) on March 27, 2025 and Clearside's other Periodic Reports filed with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Clearside as of the date of this release, and Clearside assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise. Investor and Media Contacts: Jenny Kobin Remy Bernarda [email protected]
